News & Updates
Filter by Specialty:
No trade-off between bleeding and ischaemic risk with abbreviated DAPT
Stopping dual antiplatelet therapy (DAPT) after 1 month appeared safe in high-bleeding risk (HBR) patients with acute myocardial infarction (MI) who were implanted with a newer coronary stent, a prespecified subanalysis of the MASTER DAPT* trial has shown.
No trade-off between bleeding and ischaemic risk with abbreviated DAPT
19 Nov 2021
Liver injury persists in patients with vaccine breakthrough COVID-19
Liver injury is not uncommon among patients with vaccine breakthrough COVID-19, indicating the importance of monitoring liver injury enzymes, according to a study presented at The Liver Meeting 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).
Liver injury persists in patients with vaccine breakthrough COVID-19
18 Nov 2021
Resveratrol supplements confer minimal benefits in T2D, MetS, NAFLD
Supplementation with resveratrol does not appear to provide much benefit in the management of cardiometabolic risk factors in patients with type 2 diabetes (T2D), metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD), suggests a study.
Resveratrol supplements confer minimal benefits in T2D, MetS, NAFLD
18 Nov 2021
Subgroup findings boost dupilumab benefit for CRSwNP, comorbid asthma
In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.
